Please assess the completion status of the following clinical trial:

Trial Title: Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subjects (absence of disease) between 18 and 50 years of age.~2. Must be in general good health with no disease or physical conditions that would impair evaluation of itch and pain perception.~3. No history of chronic itch or pain.~4. Must abstain from the use of any systemic or topical anti-histamine, steroid, or pain relief medications 48 hours prior to the study visits.~5. Must abstain from the use of moisturizers on the arms the day of study visit.~Exclusion Criteria:~1. Individuals under 18 or over 50 years of age.~2. Inability to complete the required measures.~3. The presence of an itchy skin disease or a painful condition.~4. Diagnosis of diseased that would affect itch or pain perception (e.g. neuropathies).~5. Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy.~6. Use of oral, topical analgesics, or other medications known to interfere with itch or pain perception 48 hours prior to the study visits (e.g. antihistamines, anesthetics, anti-inflammatories, opioids, neuroleptics, etc.).~7. Use of emollients on the volar aspects of the forearms arms on the day of the study visit.~8. Use of anti-depressants, anti-psychotics, and illicit drugs.~9. Known history of neuropathy, uremia, uncontrolled thyroid disease, and diabetes mellitus.~10. Known history of anaphylactic shock, or allergy to cowhage and/or known adverse reactions to lidocaine (or other local anesthetics of the amide type), ketamine or amitriptyline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Topical KeAmLi combo (Type: EXPERIMENTAL): Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
- Topical ketamine (Type: EXPERIMENTAL): Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
- Topical amitriptyline (Type: EXPERIMENTAL): Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
- Topical lidocaine (Type: EXPERIMENTAL): Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
- Topical vehicle (Type: PLACEBO_COMPARATOR): Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.

Based on this trial design, predict the completion outcome and termination type (if applicable).